Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fate Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zevra Therapeutics (ZVRA), Fate Therapeutics (FATE) ...

Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Fate Therapeutics (FATE) and Mirum Pharmaceuticals (MIRM)

FTSE Russell has released its preliminary changes for the Russell 3000 Index ahead of the official rebalancing on June 26, putting several healthca...

5 Healthcare Stocks Set to Join the Russell 3000

Analysts are intrested in these 5 stocks: ( ($CTXR) ), ( ($AMT) ), ( ($JAZZ) ), ( ($CTMX) ) and ( ($FATE) ). Here is a breakdown of their recent


CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts

Bank of America Securities analyst Tazeen Ahmad reiterated a Hold rating on Fate Therapeutics yesterday and set a price target of $2.20. The compan...

Bank of America Securities Keeps Their Hold Rating on Fate Therapeutics (FATE)

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Fate Therapeutics today and set a price target of $6.00. Tenthoff covers the Healt...

Market Cap	$137.24M	P/E Ratio	N/A
52W High	$2.47	52W Low	$0.91
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	26.6%	52W Position	79.7%
Overall Score	61	Value Score	60
Quality Score	42	Technical Score	81

EPS Current Est	$-1.07	EPS Next Est	$-0.99
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FATE	$2.15	-4.44%	5.57M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FATE	$2.15	-4.4%	5.57M
3
4
5
6

FATE

FATE

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Fate Therapeutics Inc. Data in Excel

Get Fate Therapeutics Inc. Data in Excel